Priyesh A Patel1, Li Liang2, Prateeti Khazanie2, Bradley G Hammill2, Gregg C Fonarow2, Clyde W Yancy2, Deepak L Bhatt2, Lesley H Curtis2, Adrian F Hernandez2. 1. From the Duke Clinical Research Institute, Durham, NC (P.A.P., L.L., P.K., B.G.H., L.H.C., A.F.H.); Ronald Reagan University of California Los Angeles Medical Center (G.C.F.); Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (C.W.Y.); Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.); and Duke University Medical Center, Durham, NC (A.F.H.). priyesh.patel@dm.duke.edu. 2. From the Duke Clinical Research Institute, Durham, NC (P.A.P., L.L., P.K., B.G.H., L.H.C., A.F.H.); Ronald Reagan University of California Los Angeles Medical Center (G.C.F.); Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (C.W.Y.); Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.); and Duke University Medical Center, Durham, NC (A.F.H.).
Abstract
BACKGROUND: Diabetes mellitus, heart failure (HF), and chronic kidney disease are common comorbidities, but overall use and safety of antihyperglycemic medications (AHMs) among patients with these comorbidities are poorly understood. METHODS AND RESULTS: Using Get With the Guidelines-Heart Failure and linked Medicare Part D data, we assessed AHM use within 90 days of hospital discharge among HF patients with diabetes mellitus discharged from Get With the Guidelines-Heart Failure hospitals between January 1, 2006, and October 1, 2011. We further summarized use by renal function and assessed renal contraindicated AHM use for patients with estimated glomerular filtration rate <30 mL/min/1.73m(2). Among 8791 patients meeting inclusion criteria, the median age was 77 (interquartile range 71-83), 62.3% were female, median body mass index was 29.7 (interquartile range 25.5-35.3), median hemoglobin A1c was 6.8 (interquartile range 6.2-7.8), and 34% had ejection fraction <40%. 74.9% of patients filled a prescription for an AHM, with insulin (39.5%), sulfonylureas (32.4%), and metformin (17%) being the most commonly used AHMs. Insulin use was higher and sulfonylurea/metformin use was lower among patients with lower renal function classes. Among 1512 patients with estimated glomerular filtration rate <30 mL/min/1.73m(2), 35.4% filled prescriptions for renal contraindicated AHMs per prescribing information, though there was a trend toward lower renal contraindicated AHM use over time (Cochran-Mantel-Haenszel row-mean score test P=0.048). Although use of other AHMs was low overall, thiazolidinediones were used in 6.6% of HF patients, and dipeptidyl peptidase-4 inhibitors were used in 5.1%, with trends for decreasing thiazolidinedione use and increased dipeptidyl peptidase-4 inhibitor use over time (P<0.001). CONCLUSIONS: Treatment of diabetes mellitus in patients with HF and chronic kidney disease is complex, and these patients are commonly treated with renal contraindicated AHMs, including over 6% receiving a thiazolidinedione, despite known concerns regarding HF. More research regarding safety and efficacy of various AHMs among HF patients is needed.
BACKGROUND:Diabetes mellitus, heart failure (HF), and chronic kidney disease are common comorbidities, but overall use and safety of antihyperglycemic medications (AHMs) among patients with these comorbidities are poorly understood. METHODS AND RESULTS: Using Get With the Guidelines-Heart Failure and linked Medicare Part D data, we assessed AHM use within 90 days of hospital discharge among HF patients with diabetes mellitus discharged from Get With the Guidelines-Heart Failure hospitals between January 1, 2006, and October 1, 2011. We further summarized use by renal function and assessed renal contraindicated AHM use for patients with estimated glomerular filtration rate <30 mL/min/1.73m(2). Among 8791 patients meeting inclusion criteria, the median age was 77 (interquartile range 71-83), 62.3% were female, median body mass index was 29.7 (interquartile range 25.5-35.3), median hemoglobin A1c was 6.8 (interquartile range 6.2-7.8), and 34% had ejection fraction <40%. 74.9% of patients filled a prescription for an AHM, with insulin (39.5%), sulfonylureas (32.4%), and metformin (17%) being the most commonly used AHMs. Insulin use was higher and sulfonylurea/metformin use was lower among patients with lower renal function classes. Among 1512 patients with estimated glomerular filtration rate <30 mL/min/1.73m(2), 35.4% filled prescriptions for renal contraindicated AHMs per prescribing information, though there was a trend toward lower renal contraindicated AHM use over time (Cochran-Mantel-Haenszel row-mean score test P=0.048). Although use of other AHMs was low overall, thiazolidinediones were used in 6.6% of HF patients, and dipeptidyl peptidase-4 inhibitors were used in 5.1%, with trends for decreasing thiazolidinedione use and increased dipeptidyl peptidase-4 inhibitor use over time (P<0.001). CONCLUSIONS: Treatment of diabetes mellitus in patients with HF and chronic kidney disease is complex, and these patients are commonly treated with renal contraindicated AHMs, including over 6% receiving a thiazolidinedione, despite known concerns regarding HF. More research regarding safety and efficacy of various AHMs among HF patients is needed.
Authors: Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz Journal: N Engl J Med Date: 2013-09-02 Impact factor: 91.245
Authors: Matthew A Cavender; Ph Gabriel Steg; Sidney C Smith; Kim Eagle; E Magnus Ohman; Shinya Goto; Julia Kuder; Kyungah Im; Peter W F Wilson; Deepak L Bhatt Journal: Circulation Date: 2015-07-07 Impact factor: 29.690
Authors: Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245
Authors: Michael R MacDonald; Mark C Petrie; Fumi Varyani; Jan Ostergren; Eric L Michelson; James B Young; Scott D Solomon; Christopher B Granger; Karl Swedberg; Salim Yusuf; Marc A Pfeffer; John J V McMurray Journal: Eur Heart J Date: 2008-04-14 Impact factor: 29.983
Authors: Dean T Eurich; Daniala L Weir; Sumit R Majumdar; Ross T Tsuyuki; Jeffrey A Johnson; Lisa Tjosvold; Saskia E Vanderloo; Finlay A McAlister Journal: Circ Heart Fail Date: 2013-03-18 Impact factor: 8.790
Authors: Yuliya Lytvyn; Petter Bjornstad; Jacob A Udell; Julie A Lovshin; David Z I Cherney Journal: Circulation Date: 2017-10-24 Impact factor: 29.690
Authors: Palvinder Kaur; Nakul Saxena; Alex Xiaobin You; Raymond C C Wong; Choon Pin Lim; Seet Yoong Loh; Pradeep Paul George Journal: BMJ Open Date: 2018-05-20 Impact factor: 2.692
Authors: Sumant P Radhoe; Jesse F Veenis; Gerard C M Linssen; Chris van der Lee; Luc W M Eurlings; Hans Kragten; Nadea Y Y Al-Windy; Aukje van der Spank; Stefan Koudstaal; Hans-Peter Brunner-La Rocca; Jasper J Brugts Journal: ESC Heart Fail Date: 2021-12-04
Authors: Gerasimos Filippatos; Stefan D Anker; Rajiv Agarwal; Luis M Ruilope; Peter Rossing; George L Bakris; Christoph Tasto; Amer Joseph; Peter Kolkhof; Andrea Lage; Bertram Pitt Journal: Circulation Date: 2021-11-13 Impact factor: 29.690